Shares of pharmaceutical firm Cipla today surged nearly 9 per cent in morning trade as the company launched its generic drug used for treatment of asthma and chronic obstructive pulmonary disease in Germany and Sweden.
Cipla's scrip jumped 8.58 per cent to Rs 575.20 -- its 52-week high on the BSE.
On the NSE, the stock soared 8.66 per cent to touch its one-year high of Rs 575.
The stock was the top gainer among the blue-chips on both Sensex and Nifty.
While the drug Salmeterol/Fluticasone MDI will be sold under the Serroflo brand in Germany, it will be marketed as Salmeterol/Fluticasone Cipla in Sweden, Cipla had said in a statement yesterday.
Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment, the company had said.
The product will be available in the strengths of 120 doses of 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone.
